KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

AbbVie (ABBV) Leases (2019 - 2025)

AbbVie (ABBV) has disclosed Leases for 7 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 93.91% to $44.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.0 million, a 93.91% decrease, with the full-year FY2025 number at $44.0 million, down 93.91% from a year prior.
  • Leases was $44.0 million for Q4 2025 at AbbVie, down from $723.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $744.0 million in Q4 2023 to a low of $25.0 million in Q4 2022.
  • A 5-year average of $313.8 million and a median of $44.0 million in 2025 define the central range for Leases.
  • Peak YoY movement for Leases: surged 2876.0% in 2023, then tumbled 93.91% in 2025.
  • AbbVie's Leases stood at $33.0 million in 2021, then decreased by 24.24% to $25.0 million in 2022, then soared by 2876.0% to $744.0 million in 2023, then fell by 2.82% to $723.0 million in 2024, then crashed by 93.91% to $44.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Leases are $44.0 million (Q4 2025), $723.0 million (Q4 2024), and $744.0 million (Q4 2023).